


Consultants Report: Q4 2024

SJVIA- EmpiRx Health – Q2 and Q3 2024 Highlights

- SJVIA's total plan cost increased in Q4-2024 by 22% to \$8,004,963 (Q4-2023 \$6,527,725)
 - o Tulare: \$3,468,351 in Plan Cost
 - o Fresno: \$4,536,613 in Plan Cost
- The increase in plan spend can be attributed to an increase in Rx count.
- Specialty claims plan cost increased slightly in Q4-2024
 - o Q4-2023 \$2,507,686 (Q4-2023 \$2,495,776)
 - 633 Scripts filled in Q4-2024 (Q4-2023 664)
 - Tulare: 266Fresno: \$407
- Patient Saver Plus Program Savings (formerly known as Variable Copay Assistance (VCAP) aka bWell)
 - SJVIA Total Savings May December: \$330,831
 - Tulare: \$166,763Fresno: \$164,068
- Rebates:
 - O Q1-2024 net rebate amount is \$1,618,600 (includes \$382,745 true up payment in August)
 - Q2 -2024 net rebate amount is \$1,730,100
 - o Q3 2024 net rebate amount is \$1,766,350
 - Q4 2024 net rebate amount is \$1,648,300
- Clinical Savings: January December 2024: \$6,939,480 (original estimate number was \$1,100,000)
 - SJVIA Tulare: Jan-Dec 2024, \$2,730,999
 - SJVIA Fresno: Jan-Jun 2024, \$4,208,481

KPS Audit

KPS conducts a yearly financial audit of EmpiRx clinical savings, Average Wholesale Price (AWP) discounts and rebate performance against the client's aggregate contractual guarantees. 2024 Audit is expected to be completed by 5/30/25



Top Clinical Cost Drivers by Drug Q1 – Q3 2024

Top Drugs by Ingredient Cost

Based on Paid Date: 01/01/2024-12/31/2024

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost
WEGOVY	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	В	3	N	1,713	364	\$2,539,310.43
MOUNJARO	ANTIDIABETICS	В	2	N	1,254	223	\$1,583,939.05
OZEMPIC	ANTIDIABETICS	В	2	N	1,057	327	\$1,440,156.48
DUPIXENT	DERMATOLOGICALS	В	2	Υ	246	42	\$958,800.58
JARDIANCE	ANTIDIABETICS	В	2	N	562	169	\$783,515.21
OZEMPIC (2 MG/DOSE)	ANTIDIABETICS	В	2	N	514	157	\$705,691.82
ZEPBOUND	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	В	3	N	558	147	\$645,540.27
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	В	2	Υ	71	22	\$569,205.60
OZEMPIC (1 MG/DOSE)	ANTIDIABETICS	В	2	N	391	159	\$544,276.36
EMPAVELI	HEMATOLOGICAL AGENTS - MISC.	В	2	Υ	13	1	\$509,733.51
STELARA	DERMATOLOGICALS	В	2	Υ	17	6	\$457,903.54
TREMFYA	DERMATOLOGICALS	В	2	Υ	33	10	\$440,211.79
TRULICITY	ANTIDIABETICS	В	2	N	306	82	\$413,004.23
RYBELSUS	ANTIDIABETICS	В	2	N	232	70	\$411,397.53
OZEMPIC (0.25 OR 0.5 MG/DOSE)	ANTIDIABETICS	В	2	N	354	158	\$405,045.54
HUMIRA (2 PEN)	ANALGESICS - ANTI-INFLAMMATORY	В	2	Υ	55	18	\$404,807.03
FARXIGA	ANTIDIABETICS	В	2	N	271	106	\$400,926.26
SKYRIZI PEN	DERMATOLOGICALS	В	2	Υ	19	8	\$394,201.61
RINVOQ	ANALGESICS - ANTI-INFLAMMATORY	В	2	Υ	55	10	\$371,675.64
ELIQUIS	ANTICOAGULANTS	В	2	N	315	82	\$338,629.68
JANUVIA	ANTIDIABETICS	В	2	N	250	77	\$336,202.00
BIKTARVY	ANTIVIRALS	В	2	Υ	83	11	\$329,806.51
TRIKAFTA	RESPIRATORY AGENTS - MISC.	В	2	Υ	11	1	\$304,854.22
PAXLOVID (300/100)	ANTIVIRALS	В	2	N	200	224	\$298,306.98
KORLYM	ANTIDIABETICS	В	3	Υ	7	1	\$288,953.54

New Medications Available in the Market

New Biosimilar's in 2025

Avtozma (tocilizumab-anoh):

Approved in January 2025, this biosimilar to Actemra (tocilizumab) is indicated for rheumatoid arthritis,
 giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic JIA.

Merilog (insulin aspart-szjj):

Approved in February 2025, this is the first biosimilar to NovoLog (insulin aspart). It is a rapid-acting insulin
product for the treatment of type 1 and type 2 diabetes.

Ospomyvtm and Xbryktm (denosumab-dssb):

 These biosimilars to Prolia and Xgeva (denosumab) were approved in February 2025. They are used for treating osteoporosis, bone metastases, and other bone-related conditions.

Omlyclo (omalizumab-igec)

- Approved in March, the first and only biosimilar designated as interchangeable with Xolari (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU)
- EmpiRx will be reviewing Formulary placement of these biosimilar's once they become available.

